Allianz Asset Management GmbH increased its position in LeMaitre Vascular Inc (NASDAQ:LMAT) by 8.2% during the fourth quarter, HoldingsChannel.com reports. The fund owned 348,087 shares of the medical instruments supplier’s stock after purchasing an additional 26,267 shares during the quarter. Allianz Asset Management GmbH’s holdings in LeMaitre Vascular were worth $11,083,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently added to or reduced their stakes in the stock. Northern Trust Corp increased its stake in LeMaitre Vascular by 9.8% during the 2nd quarter. Northern Trust Corp now owns 239,671 shares of the medical instruments supplier’s stock valued at $7,483,000 after buying an additional 21,473 shares during the period. Vanguard Group Inc. increased its stake in LeMaitre Vascular by 23.5% during the 2nd quarter. Vanguard Group Inc. now owns 815,580 shares of the medical instruments supplier’s stock valued at $25,462,000 after buying an additional 155,249 shares during the period. Voya Investment Management LLC acquired a new position in LeMaitre Vascular during the 2nd quarter valued at about $203,000. Royal Bank of Canada increased its stake in LeMaitre Vascular by 856.5% during the 2nd quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock valued at $157,000 after buying an additional 4,505 shares during the period. Finally, State Street Corp increased its stake in LeMaitre Vascular by 25.2% during the 2nd quarter. State Street Corp now owns 382,824 shares of the medical instruments supplier’s stock valued at $11,951,000 after buying an additional 77,009 shares during the period. 72.88% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have commented on LMAT shares. BidaskClub raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Wednesday, February 28th. Finally, Canaccord Genuity reissued a “hold” rating and set a $33.00 target price on shares of LeMaitre Vascular in a research note on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $34.00.
LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, February 21st. The medical instruments supplier reported $0.21 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The firm had revenue of $26.15 million for the quarter, compared to analysts’ expectations of $26.23 million. LeMaitre Vascular had a net margin of 17.03% and a return on equity of 16.93%. LeMaitre Vascular’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the company earned $0.13 EPS. research analysts anticipate that LeMaitre Vascular Inc will post 0.98 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 5th. Stockholders of record on Thursday, March 22nd will be paid a $0.07 dividend. The ex-dividend date of this dividend is Wednesday, March 21st. This represents a $0.28 annualized dividend and a dividend yield of 0.76%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.06. LeMaitre Vascular’s payout ratio is currently 25.88%.
In other news, Chairman George W. Lemaitre sold 45,000 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $34.66, for a total value of $1,559,700.00. Following the transaction, the chairman now owns 3,225,709 shares of the company’s stock, valued at approximately $111,803,073.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 5,700 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $35.56, for a total transaction of $202,692.00. Following the completion of the transaction, the chief executive officer now directly owns 3,259,263 shares in the company, valued at approximately $115,899,392.28. The disclosure for this sale can be found here. Insiders sold a total of 137,736 shares of company stock worth $4,866,186 in the last ninety days. Corporate insiders own 23.70% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Allianz Asset Management GmbH Has $11.08 Million Position in LeMaitre Vascular Inc (LMAT)” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3256581/allianz-asset-management-gmbh-has-11-08-million-position-in-lemaitre-vascular-inc-lmat.html.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.